60,479 Natera, Inc. $NTRA Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC boosted its holdings in Natera, Inc. (NASDAQ:NTRA – Free Report) by 23.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 313,089 shares of the medical research company’s stock after buying an additional 60,479 shares during the period. Voya Investment Management LLC owned 0.22% of Natera worth $129,403,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. SYM FINANCIAL Corp grew its holdings in Natera by 1.7% during the 3rd quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company’s stock valued at $784,000 after buying an additional 32 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Natera by 4.6% during the third quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock valued at $337,000 after buying an additional 36 shares during the last quarter. AlphaCentric Advisors LLC lifted its holdings in shares of Natera by 3.0% in the third quarter. AlphaCentric Advisors LLC now owns 1,432 shares of the medical research company’s stock worth $592,000 after buying an additional 42 shares in the last quarter. VestGen Advisors LLC lifted its holdings in shares of Natera by 3.1% in the third quarter. VestGen Advisors LLC now owns 1,460 shares of the medical research company’s stock worth $603,000 after buying an additional 44 shares in the last quarter. Finally, Parallel Advisors LLC lifted its holdings in shares of Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, CFO Michael Brophy sold 1,906 shares of the business’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $425.55, for a total value of $811,098.30. Following the sale, the chief financial officer owned 46,574 shares in the company, valued at approximately $19,819,565.70. The trade was a 3.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 15,160 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the sale, the insider directly owned 110,859 shares in the company, valued at approximately $36,238,698.51. The trade was a 12.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 47,056 shares of company stock valued at $17,760,989. 5.05% of the stock is owned by corporate insiders.

Natera Price Performance

NASDAQ:NTRA opened at $289.50 on Thursday. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41. The stock’s 50 day simple moving average is $377.35 and its two-hundred day simple moving average is $272.44. The company has a market cap of $41.98 billion, a price-to-earnings ratio of -253.95 and a beta of 1.55.

Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The firm had revenue of $793.98 million for the quarter, compared to analysts’ expectations of $707.54 million. Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. The firm’s revenue was up 34.1% on a year-over-year basis. During the same period last year, the company earned ($0.64) earnings per share. As a group, analysts anticipate that Natera, Inc. will post -1.25 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Barclays raised their target price on shares of Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. BTIG Research lifted their price target on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. Piper Sandler reiterated an “overweight” rating and issued a $363.50 price target on shares of Natera in a research note on Friday, November 6th. Leerink Partners set a $330.00 price objective on shares of Natera in a report on Friday, August 7th. Finally, Canaccord Genuity Group raised their price objective on Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $394.31.

Read Our Latest Analysis on Natera

Natera Profile

(Free Report)

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

Further Reading

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.